bepridil has been researched along with Hemorrhage in 1 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 8.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| "In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1." | 4.31 | Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komatsu, Y | 1 |
| Yodoshi, M | 1 |
| Takegami, M | 1 |
| Yokoyama, S | 1 |
| Hosomi, K | 1 |
1 other study available for bepridil and Hemorrhage
| Article | Year |
|---|---|
Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Atrial Fibrillation; | 2023 |